Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) (ITUB) vs Novo Nordisk A/S (NVO) Price & Performance

Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares)Trade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) vs Novo Nordisk A/S — how do they compare? Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) trades at $9.9 (market cap $113.15B), while Novo Nordisk A/S trades at $38.07 (market cap $168.73B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.7%). Which is the better fit depends on your goals — on Pluang, investors hold Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) for 0 Days and Novo Nordisk A/S for 116 Days on average.

ITUBNVO
Market Cap
$113.15B$168.73B
Volume
41,687,32013,531,267
Sector
FinancialsHealth
52-Week High
$10.15$63.98
52-Week Low
$6.76$35.29
Typical Hold Time
0 Days116 Days
Enterprise Value
$1.32T$183.05B
Dividend Yield
1.76%4.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares)

No Aura AI signal available yet.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $38.18, up 1.73% with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat estimates, with Q2 2026 EPS of $0.96 surpassing the $0.82 expectation. The company maintains robust cash flow generation of $119.1B from operations in 2025.

NVO presents compelling value with a 9.71 P/E ratio and 16.8% upside to the $44.67 consensus target. Key risks include FDA regulatory delays for hemophilia drug denecimig and intensifying competition from Eli Lilly in obesity treatments. The bullish analyst consensus (59% buy ratings) supports the growth outlook despite near-term headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ITUB
100% Buy0% Sell
Avg holding period · 0 Days
NVO
68% Buy32% Sell
Avg holding period · 116 Days

Top news

Latest headlines on both assets

About Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares)

Itaú Unibanco is a Brazilian financial services company providing banking, credit, insurance, and investment products. It serves individual, business, and corporate clients.

Read more on ITUB →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO →